| 371 |
Variability in response to cardiovascular drugs |
2006 |
| 372 |
Transport of proserine through blood brain barrier using poly(butylcyanoacrylate) nanoparticles coated with polysorbate-80 in rats. |
2005 |
| 373 |
Antiamnesic activity of nerve growth factor adsorbed on poly(butyl) cyanoacrylate nanoparticles coated with polysorbate-80. |
2005 |
| 374 |
Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense? American Journal of Therapeutics 2005;12: 320-7. |
2005 |
| 375 |
Brain targeting of nerve growth factor using poly(butylcyanoacrylate) nanoparticles. |
2005 |
| 376 |
NAT*5/5 Genotype (341T>C ) Is A Potential Risk Factor For Schistosomiasis- Associated Bladder Caner In Egyptians |
2005 |
| 377 |
Pharmacological Evidence for the Role of Nitric Oxide-cGMP in antinociception. |
2005 |
| 378 |
Study of urinary 6 beta-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population. |
2005 |
| 379 |
Aminoglycoside and vancomycin serum concentration monitoring and mortality due to neonatal sepsis in Saudi Arabia.
|
2004 |
| 380 |
Evaluation of therapeutic drug monitoring of Valproic acid : a 6-years experience in upper Egypt |
2004 |
هل لديك سؤال ؟
